JP2019520034A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520034A5
JP2019520034A5 JP2018550322A JP2018550322A JP2019520034A5 JP 2019520034 A5 JP2019520034 A5 JP 2019520034A5 JP 2018550322 A JP2018550322 A JP 2018550322A JP 2018550322 A JP2018550322 A JP 2018550322A JP 2019520034 A5 JP2019520034 A5 JP 2019520034A5
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018550322A
Other languages
English (en)
Japanese (ja)
Other versions
JP7491666B2 (ja
JP2019520034A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/059071 external-priority patent/WO2017178653A2/en
Publication of JP2019520034A publication Critical patent/JP2019520034A/ja
Publication of JP2019520034A5 publication Critical patent/JP2019520034A5/ja
Priority to JP2022112873A priority Critical patent/JP7549626B2/ja
Application granted granted Critical
Publication of JP7491666B2 publication Critical patent/JP7491666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018550322A 2016-04-14 2017-04-14 新規な抗SIRPa抗体およびそれらの治療適用 Active JP7491666B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022112873A JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662322707P 2016-04-14 2016-04-14
US62/322,707 2016-04-14
EP17305182 2017-02-17
EP17305182.2 2017-02-17
PCT/EP2017/059071 WO2017178653A2 (en) 2016-04-14 2017-04-14 NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022112873A Division JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Publications (3)

Publication Number Publication Date
JP2019520034A JP2019520034A (ja) 2019-07-18
JP2019520034A5 true JP2019520034A5 (enExample) 2020-05-21
JP7491666B2 JP7491666B2 (ja) 2024-05-28

Family

ID=65529144

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018550322A Active JP7491666B2 (ja) 2016-04-14 2017-04-14 新規な抗SIRPa抗体およびそれらの治療適用
JP2022112873A Active JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022112873A Active JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Country Status (24)

Country Link
US (3) US11279766B2 (enExample)
EP (1) EP4438626A3 (enExample)
JP (2) JP7491666B2 (enExample)
KR (1) KR102355240B1 (enExample)
CN (1) CN115785272A (enExample)
CL (1) CL2018002898A1 (enExample)
DK (1) DK3443010T3 (enExample)
ES (1) ES2990971T3 (enExample)
FI (1) FI3443010T3 (enExample)
HR (1) HRP20241316T1 (enExample)
HU (1) HUE068840T2 (enExample)
IL (1) IL262251B2 (enExample)
LT (1) LT3443010T (enExample)
MA (1) MA44665B1 (enExample)
MD (1) MD3443010T2 (enExample)
MX (1) MX2018012434A (enExample)
PH (1) PH12018550160B1 (enExample)
PL (1) PL3443010T3 (enExample)
RS (1) RS66062B1 (enExample)
SA (1) SA518400237B1 (enExample)
SI (1) SI3443010T1 (enExample)
SM (1) SMT202400438T1 (enExample)
UA (1) UA126658C2 (enExample)
ZA (1) ZA201806293B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12018550160B1 (en) * 2016-04-14 2024-07-03 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
EP3658589B1 (en) * 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
CN111511766B (zh) 2017-10-13 2024-06-07 Ose免疫疗法 修饰的抗SIRPa抗体及其应用
BR112020017709A2 (pt) 2018-03-13 2020-12-29 Ose Immunotherapeutics Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos
WO2019183266A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
CN112574310B (zh) 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
KR102896511B1 (ko) * 2022-09-07 2025-12-08 주식회사 시프트바이오 SIRPα 변이체에 특이적으로 결합하는 항체

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP1244707A1 (de) 1999-11-30 2002-10-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
US20100215640A1 (en) * 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
JP3936673B2 (ja) 2003-06-02 2007-06-27 国立大学法人群馬大学 Cd47部分ペプチドと抗shps−1モノクロナール抗体
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
JP2011500005A (ja) 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク ヒト造血幹細胞の生着を増加させるためのSIRPα−CD47相互作用の調節およびそのための化合物
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
DK2429574T3 (da) 2009-05-15 2015-06-22 Univ Health Network Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
WO2012149416A2 (en) 2011-04-28 2012-11-01 University Of Southern California Human myeloid derived suppressor cell cancer markers
MX2013014789A (es) * 2011-06-16 2014-01-20 Novartis Ag Proteinas solubles para utilizarse como productos terapeuticos.
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
EP3766511A1 (en) 2012-01-17 2021-01-20 The Board of Trustees of the Leland Stanford Junior University High affinity sirp-alpha reagents
SG10201706383XA (en) 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
CN105085679B (zh) * 2014-04-25 2019-01-11 上海津曼特生物科技有限公司 全人源抗rankl抗体
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
US10618976B2 (en) 2015-06-16 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University SIRP-α agonist antibody
DK4186927T3 (da) 2015-10-21 2025-06-10 Ose Immunotherapeutics Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft
PH12018550160B1 (en) * 2016-04-14 2024-07-03 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
PT3443010T (pt) 2017-02-17 2024-10-21 Ose Immunotherapeutics Novos anticorpos anti-sirpa e suas aplicações terapêuticas
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
PT3625259T (pt) 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
EP3658589B1 (en) 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
CN111511766B (zh) 2017-10-13 2024-06-07 Ose免疫疗法 修饰的抗SIRPa抗体及其应用
BR112020017709A2 (pt) 2018-03-13 2020-12-29 Ose Immunotherapeutics Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos
WO2019183266A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
MX2020013068A (es) 2018-07-10 2021-03-02 Univ Kobe Nat Univ Corp Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
EP3833391A4 (en) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
BR112021009325A2 (pt) 2018-11-14 2021-09-14 Arch Oncology, Inc. Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
CN113412279B (zh) 2018-11-15 2024-09-24 拜奥迪斯私人有限公司 人源化抗SIRPα抗体
US20220235144A1 (en) 2019-03-04 2022-07-28 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
US20210347908A1 (en) 2019-08-20 2021-11-11 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
CN111635458B (zh) 2020-03-20 2026-02-17 健信生物科技(宁波)有限公司 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
CN112010979B (zh) 2020-08-21 2022-05-10 博奥信生物技术(南京)有限公司 一种抗人SIRPα单克隆抗体及其用途
CN111995682B (zh) 2020-08-21 2022-05-10 博奥信生物技术(南京)有限公司 抗人SIRPα单克隆抗体及其用途
CN112574310B (zh) 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途

Similar Documents

Publication Publication Date Title
JP2022169504A5 (enExample)
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
TWI701259B (zh) 4﹘1bb抗體及其製備方法和應用
US9273136B2 (en) Fully human anti-human NKG2D monoclonal antibodies
CN113543804A (zh) 抗lilrb2抗体及其使用方法
BR112021010394A2 (pt) Anticorpo anti-4-1bb e uso do mesmo
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN116239698A (zh) 双功能融合蛋白及其医药用途
JP2020504095A (ja) 抗PD−L1抗体との組み合わせのための抗Tim−3抗体
JP2020504171A (ja) 抗PD−1抗体との組み合わせのための抗Tim−3抗体
JP2018531914A (ja) CD155/TIGIT経路およびTGF−βのアンタゴニストを介してがんを処置するための組成物および方法
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
CN116693686A (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
KR20200079561A (ko) Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN107266571A (zh) 抗‑mcam抗体及相关使用方法
CN112969714A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
SG187945A1 (en) Anti-ox40 antibodies and methods of using the same
KR20100014588A (ko) 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
AU2013206788A1 (en) Method of providing monoclonal auto-antibodies with desired specificity
CA3121420A1 (en) Anti-il-27 antibodies and uses thereof
CN115785272A (zh) 新型抗-SIRPa抗体及其治疗应用
US20210379194A1 (en) Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
US20150125397A1 (en) Dual specific binding proteins directed against immune cell receptors and autoantigens
WO2022143552A1 (zh) Pd-1结合分子及其应用
CN109384845B (zh) 一种cd40单克隆抗体、其制备方法及其应用